Streetbeat News

RBOT

Vicarious Surgical Inc.

https://www.vicarioussurgical.com

Industry

Medical - Devices

Vicarious Surgical Inc. engages in developing and selling single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. It offers Vicarious System, a single-incision surgical robot for ventral hernia repair. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Open

7.81

Mkt cap

50M

Volume

17K

High

8.49

P/E Ratio

-0.83

52-wk high

21.42

Low

7.81

Div yield

N/A

52-wk low

4.27

Vicarious Surgical shares are trading lower after the company announced a reverse stock split.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 8:27 pm

Vicarious Surgical (RBOT) announced a 1-for-30 reverse stock split for its Class A and Class B common stock, effective June 12, 2024. The stock will trade on a post-split basis on June 13, 2024.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 8:17 pm

The article highlights the performance of 12 healthcare stocks during Wednesday's after-market session. Notable gainers include Anitra (AZTR), Oragenics (OGEN), PACS Group (PACS), MultiPlan (MPLN), Nanoviricides (NNVC), and Calidi Biotherapeutics (CLDI). On the losing side, Matinas BioPharma (MTNB), Theriva Biologics (TOVX), Concord Medical Services (CCM), Emergent BioSolutions (EBS), Senseonics Holdings (SENS), and Vicarious Surgical (RBOT) saw declines.

Portfolio Pulse from Benzinga Insights

June 05, 2024 | 8:31 pm

The article highlights the pre-market movements of various health care stocks on Thursday. Notable gainers include OneMedNet (ONMD), iSpecimen (ISPC), P3 Health Partners (PIII), Bicycle Therapeutics (BCYC), Calliditas Therapeutics (CALT), and AEON Biopharma (AEON). On the losing side, Ensysce Biosciences (ENSC), Cytokinetics (CYTK), DermTech (DMTK), SILO Pharma (SILO), Tango Therapeutics (TNGX), and Vicarious Surgical (RBOT) saw declines.

Portfolio Pulse from Benzinga Insights

May 23, 2024 | 12:06 pm

Vicarious Surgical (NYSE:RBOT) reported Q1 2024 adjusted EPS losses of $(0.09), surpassing the consensus estimate of $(0.10) by 10%. This represents a 47.06% improvement over the $(0.17) per share losses from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 8:24 pm

In Friday's after-market session, several healthcare stocks showed significant movement. Salarius Pharmaceuticals, Masimo, and Vicarious Surgical were among the top gainers, with Salarius Pharmaceuticals leading with a 33.9% increase. On the downside, NextCure, Rockwell Medical, and Mesoblast experienced declines, with NextCure dropping 9.5% following its Q4 earnings report. These movements reflect the dynamic nature of the healthcare stock market.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 9:33 pm

In Thursday's after-market session, several healthcare stocks showed significant movement. Biolase, Terns Pharma, Aptevo Therapeutics, Nexalin Technology, Evolus, and Phio Pharma were among the gainers, with Biolase leading by a 20% increase following their Q4 earnings release. On the downside, Cutera, Hyperfine, China SXT Pharmaceuticals, Vicarious Surgical, Meihua Intl Medical Techs, and Assure Holdings experienced declines, with Cutera dropping 11.7% after their Q4 earnings announcement.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 9:33 pm

In Wednesday's after-market session, several healthcare stocks showed significant movement. SCWorx (WORX) led the gainers with a 60.8% increase, while Nexalin Technology (NXL) experienced the largest drop among the losers, falling 14.4%. Notable mentions include IO Biotech (IOBT) and Vicarious Surgical (RBOT), which released their Q4 earnings recently, influencing their stock movements.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 9:31 pm

SOPHiA GENETICS shares fell by 19% after reporting Q4 earnings below expectations and issuing weak 2024 guidance. Other stocks showed significant movement, with Sunshine Biopharma, Airship AI Holdings, and AeroVironment among the top gainers, while Quoin Pharmaceuticals, Crawford & Company, and Ekso Bionics led the losers.

Portfolio Pulse from Avi Kapoor

March 05, 2024 | 6:11 pm

Piper Sandler analyst Adam Maeder has maintained a Neutral rating on Vicarious Surgical (NYSE:RBOT) and lowered the price target from $1.5 to $1.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 2:03 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.